Market closedNon-fractional

Revance Therapeutics/RVNC

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Revance Therapeutics

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

Ticker

RVNC

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Nashville, United States

Employees

597

RVNC Metrics

BasicAdvanced
$279M
Market cap
-
P/E ratio
-$3.64
EPS
1.05
Beta
-
Dividend rate
$279M
1.05
5.365
4.455
-469.886
-482.175
-10.98%
-26.14%
518.63%
0.97
-2.84
-2.61
-1.056
56.91%
-21.56%
103.35%
-8.64%

What the Analysts think about RVNC

Analyst Ratings

Majority rating from 12 analysts.
Buy

RVNC Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-102.31% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$52M
-25.54%
Net income
-$53M
-4.50%
Profit margin
-102.31%
28.26%

RVNC Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 22.67%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.80
-$1.63
-$0.62
-$0.58
-
Expected
-$0.78
-$0.85
-$0.72
-$0.75
-$0.53
Surprise
2.86%
91.09%
-14.38%
-22.67%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Revance Therapeutics stock?

Revance Therapeutics (RVNC) has a market cap of $279M as of July 06, 2024.

What is the P/E ratio for Revance Therapeutics stock?

The price to earnings (P/E) ratio for Revance Therapeutics (RVNC) stock is 0 as of July 06, 2024.

Does Revance Therapeutics stock pay dividends?

No, Revance Therapeutics (RVNC) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Revance Therapeutics dividend payment date?

Revance Therapeutics (RVNC) stock does not pay dividends to its shareholders.

What is the beta indicator for Revance Therapeutics?

Revance Therapeutics (RVNC) has a beta rating of 1.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Revance Therapeutics stock

Buy or sell Revance Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing